Literature DB >> 9632365

Comprehensive study on structure-activity relationships of rifamycins: discussion of molecular and crystal structure and spectroscopic and thermochemical properties of rifamycin O.

A Bacchi1, G Pelizzi, M Nebuloni, P Ferrari.   

Abstract

The mechanism of action of rifamycins against bacterial DNA-dependent RNA polymerase has been explained on the basis of the spatial arrangement of four oxygens which can form hydrogen bonds with the enzyme. Structural descriptors are derived from X-ray diffraction crystal structures of 25 active and nonactive rifamycins. Principal component analysis is used to find the combination of structural parameters which better discriminate between active and nonactive rifamycins. Two possible mechanisms of molecular rearrangement are described which can convert nonactive into active conformations. The energy involved for conformational rearrangements is studied by molecular modeling techniques. Methyl C34 is found to play a key role for determining the geometry of the pharmacophore. Rifamycin O, reported to be active, is obtained by oxidation of rifamycin B and is studied by X-ray single-crystal diffractometry, by solution IR and NMR spectroscopy, and by thermal analysis. Surprisingly the oxidation process is totally stereospecific, and an explanation is given based on solution spectroscopic evidence. The conformation found in the solid state is typical of nonactive compounds, and molecular mechanics calculations show that a molecular rearrangement to the active conformation would require about 15 kcal/mol. Thermal analysis confirms that rifamycin O has a sterically constrained conformation. Therefore, it is likely that the antibiotic activity of rifamycin O is due either to chemical modification prior to reaching the enzyme or to conformational activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632365     DOI: 10.1021/jm970791o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Conformational variety for the ansa chain of rifamycins: comparison of observed crystal structures and molecular dynamics simulations.

Authors:  A Bacchi; G Pelizzi
Journal:  J Comput Aided Mol Des       Date:  1999-07       Impact factor: 3.686

2.  Synthesis and characterization of antibacterial drug loaded β-tricalcium phosphate powders for bone engineering applications.

Authors:  Aysenur Topsakal; Nazmi Ekren; Osman Kilic; Faik N Oktar; Mahir Mahirogullari; Ozan Ozkan; Hilal Turkoglu Sasmazel; Mustafa Turk; Iuliana M Bogdan; George E Stan; Oguzhan Gunduz
Journal:  J Mater Sci Mater Med       Date:  2020-01-21       Impact factor: 3.896

3.  Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism.

Authors:  James Peek; Mirjana Lilic; Daniel Montiel; Aleksandr Milshteyn; Ian Woodworth; John B Biggins; Melinda A Ternei; Paula Y Calle; Michael Danziger; Thulasi Warrier; Kohta Saito; Nathaniel Braffman; Allison Fay; Michael S Glickman; Seth A Darst; Elizabeth A Campbell; Sean F Brady
Journal:  Nat Commun       Date:  2018-10-08       Impact factor: 14.919

4.  Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis.

Authors:  Hamed Mosaei; Vadim Molodtsov; Bernhard Kepplinger; John Harbottle; Christopher William Moon; Rose Elizabeth Jeeves; Lucia Ceccaroni; Yeonoh Shin; Stephanie Morton-Laing; Emma Claire Louise Marrs; Corinne Wills; William Clegg; Yulia Yuzenkova; John David Perry; Joanna Bacon; Jeff Errington; Nicholas Edward Ellis Allenby; Michael John Hall; Katsuhiko S Murakami; Nikolay Zenkin
Journal:  Mol Cell       Date:  2018-09-20       Impact factor: 17.970

5.  Rifamycin O, An Alternative Anti-Mycobacterium abscessus Agent.

Authors:  Bui Thi Bich Hanh; June-Woo Park; Tae Ho Kim; Jae-Sung Kim; Chul-Su Yang; Kiseok Jang; Jinsheng Cui; Dong-Chan Oh; Jichan Jang
Journal:  Molecules       Date:  2020-03-31       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.